{"id":539016,"date":"2021-09-16T07:18:08","date_gmt":"2021-09-16T11:18:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/"},"modified":"2021-09-16T07:18:08","modified_gmt":"2021-09-16T11:18:08","slug":"vectivbio-announces-upcoming-investor-events","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/","title":{"rendered":"VectivBio Announces Upcoming Investor Events"},"content":{"rendered":"

\nCompany to host an R&D Day on September 21, 2021
\n<\/h2>\n
\n

BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG (\u201cVectivBio\u201d) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced\u00a0upcoming investor events. <\/p>\n

\n VectivBio R&D Day<\/strong>\n <\/p>\n

VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. \u2013 12 p.m. EDT.<\/p>\n

The Company will share the progress of its late-stage clinical candidate, apraglutide<\/em>, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases.<\/p>\n

VectivBio\u2019s management team will be joined by KOLs: Dr. Kishore Iyer, Director of Adult and Pediatric Intestinal Rehabilitation & Transplantation at Mount Sinai Medical Center<\/em>, and Dr. Robert Zeiser, Head of Tumor Immunology and Immune Modulation at the University Medical Center Freiburg<\/em>, who will discuss the latest research in SBS-IF and GVHD, respectively.<\/p>\n

The webcast can be accessed in the \u201cEvents & Presentations\u201d section of VectivBio\u2019s website at https:\/\/ir.vectivbio.com\/events-and-presentations<\/strong><\/a> and registration is now open. The presentation and Q&A session can also be accessed by dialing (855) 307-5413 (U.S.) or (929) 517-0945 (International) and entering conference ID: 3579678.<\/p>\n

\n SVB Leerink CybeRX Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event<\/strong>\n <\/p>\n

VectivBio\u2019s management team will be participating in 1×1 investor meetings at the SVB Leerink CybeRX Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event<\/em> on Thursday, September 23, 2021. To request a meeting with VectivBio, please contact your SVB Leerink representative.<\/p>\n

\n About VectivBio AG<\/strong><\/p>\n

VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. VectivBio is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio\u2019s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure. VectivBio also plans to initiate clinical studies of apraglutide in additional indications, including graft versus host disease, where GLP-2 is believed to be central to disease pathophysiology.<\/p>\n

\n Forward Looking Statements<\/strong><\/p>\n

Forward-looking statements are statements that are not historical facts. Words and phrases such as \u201canticipated,\u201d \u201cforward,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cremain,\u201d \u201cpotential,\u201d \u201cprepare,\u201d \u201cexpected,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cnear future,\u201d \u201cbelief,\u201d \u201cguidance,\u201d and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio\u2019s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic and those risks and uncertainties identified in the \u201cRisk Factors\u201d section of VectivBio\u2019s Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n

For more information visit\u00a0www.vectivbio.com<\/u><\/strong><\/a>, and follow us on\u00a0LinkedIn<\/u><\/strong><\/a> and Twitter<\/strong><\/a>.<\/p>\n

\n Investors<\/strong>
\n
Graham Morrell
graham.morrell@vectivbio.com<\/a><\/u><\/strong><\/p>\n

\n Media<\/strong>
\n
Morgan Warners
+1 (202) 295 0124
morgan.warners@fgh.com<\/a><\/u><\/strong><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host an R&D Day on September 21, 2021 BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG (\u201cVectivBio\u201d) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced\u00a0upcoming investor events. VectivBio R&D Day VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. \u2013 12 p.m. EDT. The Company will share the progress of its late-stage clinical candidate, apraglutide, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases. VectivBio\u2019s management team will be joined by KOLs: Dr. Kishore Iyer, Director of … <\/p>\n

Continue reading “VectivBio Announces Upcoming Investor Events”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-539016","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVectivBio Announces Upcoming Investor Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VectivBio Announces Upcoming Investor Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host an R&D Day on September 21, 2021 BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG (\u201cVectivBio\u201d) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced\u00a0upcoming investor events. VectivBio R&D Day VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. \u2013 12 p.m. EDT. The Company will share the progress of its late-stage clinical candidate, apraglutide, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases. VectivBio\u2019s management team will be joined by KOLs: Dr. Kishore Iyer, Director of … Continue reading "VectivBio Announces Upcoming Investor Events"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T11:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VectivBio Announces Upcoming Investor Events\",\"datePublished\":\"2021-09-16T11:18:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/\"},\"wordCount\":617,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/\",\"name\":\"VectivBio Announces Upcoming Investor Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=\",\"datePublished\":\"2021-09-16T11:18:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vectivbio-announces-upcoming-investor-events\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VectivBio Announces Upcoming Investor Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VectivBio Announces Upcoming Investor Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/","og_locale":"en_US","og_type":"article","og_title":"VectivBio Announces Upcoming Investor Events - Market Newsdesk","og_description":"Company to host an R&D Day on September 21, 2021 BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG (\u201cVectivBio\u201d) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced\u00a0upcoming investor events. VectivBio R&D Day VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. \u2013 12 p.m. EDT. The Company will share the progress of its late-stage clinical candidate, apraglutide, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases. VectivBio\u2019s management team will be joined by KOLs: Dr. Kishore Iyer, Director of … Continue reading \"VectivBio Announces Upcoming Investor Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-16T11:18:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VectivBio Announces Upcoming Investor Events","datePublished":"2021-09-16T11:18:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/"},"wordCount":617,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/","name":"VectivBio Announces Upcoming Investor Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=","datePublished":"2021-09-16T11:18:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkyNiM0NDA4MTkwIzIyMDYxMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vectivbio-announces-upcoming-investor-events\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VectivBio Announces Upcoming Investor Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=539016"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539016\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=539016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=539016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=539016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}